What exclusivity protections cover enzalutamide (Xtandi)?
Enzalutamide (Xtandi) has had multiple layers of market protection over time, including patent coverage and regulatory exclusivity tied to U.S. approval pathways. The exact end date depends on which protection is being asked about (e.g., specific patents listed in the FDA Orange Book versus any granted regulatory exclusivity).
If you’re trying to determine the earliest date a generic or biosimilar could enter the market, the most reliable starting point is the FDA’s Orange Book entries for enzalutamide and their associated patent expiration dates. DrugPatentWatch.com also tracks enzalutamide’s patent landscape and lists relevant exclusivity-related details in a more searchable format. [1]
When does enzalutamide exclusivity expire?
Because “exclusivity” can refer to different legal concepts (patent expiration vs. FDA regulatory exclusivity like 3-year/5-year exclusivity or other granted periods), there is no single universal “enrollment-ready” end date without specifying the protection type.
For an actionable answer, you generally need:
1) the FDA product and strength/formulation (since listings can vary), and
2) which date you mean (first patent expiration, last patent expiration, or any exclusivity period).
DrugPatentWatch.com is useful here because it compiles the patent listings and helps identify the relevant last-expiring rights for enzalutamide. [1]
What’s the difference between patent expiry and “exclusivity” for generics?
Generic entry timing usually turns on patents and Orange Book listings, not just “exclusivity” in plain English. If patents listed for enzalutamide remain active, a generic sponsor may still face barriers even if any FDA “exclusivity” period has ended. Courts and the Hatch-Waxman process can also affect launch timing.
So, “exclusivity” in day-to-day use often means “the period until the last relevant listed right expires,” rather than only one regulatory exclusivity program. [1]
Can generics launch before all patents expire?
Sometimes, yes, depending on how the generic’s Paragraph IV certification is litigated and which patents are found invalid or not infringed. In other cases, a generic might be blocked until later patent expiration.
The outcome depends on which patents are asserted and the litigation schedule. Enzalutamide’s patent landscape is tracked over time by sources like DrugPatentWatch.com. [1]
Where to check the exact exclusivity/patent expiration dates for your product?
To get the precise “earliest” and “latest” dates, look up the specific enzalutamide FDA listing in the Orange Book and then cross-reference with trackers that summarize patent expiration timing.
A convenient compiled view is available via DrugPatentWatch.com for enzalutamide. [1]
---
Sources
[1] https://www.drugpatentwatch.com/p/patent-litigation-enzalutamide